Low HDL-cholesterol among HIV-1 infected and HIV-1 uninfected individuals in Nairobi, Kenya

[1]  Jeffrey L. Anderson,et al.  The Evolution and Future of ACC/AHA Clinical Practice Guidelines: A 30-Year Journey A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[2]  A. Alsheikh-Ali,et al.  Cardiovascular Risk Factor Burden in Africa and the Middle East: The Africa Middle East Cardiovascular Epidemiological (ACE) Study , 2014, PloS one.

[3]  A. Schutte,et al.  Cardiometabolic markers to identify cardiovascular disease risk in HIV-infected black South Africans. , 2014, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[4]  N. Ford,et al.  The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities , 2013, Current opinion in HIV and AIDS.

[5]  J. Currier,et al.  Metabolic disease in HIV infection. , 2013, The Lancet. Infectious diseases.

[6]  P. Mallon,et al.  Dyslipidemia, atherosclerosis and cardiovascular disease: an increasingly important triad in an aging population living with HIV , 2013 .

[7]  P. van de Borne,et al.  Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon , 2013, Vascular health and risk management.

[8]  W. Fawzi,et al.  First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Budoff,et al.  HIV infection and the risk of acute myocardial infarction. , 2013, JAMA internal medicine.

[10]  R. Paredes,et al.  Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population , 2013, AIDS.

[11]  B. Richardson,et al.  HIV-1-Specific Enzyme-Linked Immunosorbent Spot Assay Responses in HIV-1-Exposed Uninfected Partners in Discordant Relationships Compared to Those in Low-Risk Controls , 2012, Clinical and Vaccine Immunology.

[12]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[13]  J. Badimón,et al.  Cardiovascular implications of HIV-induced dyslipidemia. , 2011, Atherosclerosis.

[14]  W. Fawzi,et al.  Dyslipidemia in an HIV-Positive Antiretroviral Treatment-Naive Population in Dar es Salaam, Tanzania , 2011, Journal of acquired immune deficiency syndromes.

[15]  Miles Q. Ott,et al.  Age-gaps in sexual partnerships: seeing beyond ‘sugar daddies’ , 2011, AIDS.

[16]  T. Asonganyi,et al.  Serum lipid profile in highly active antiretroviral therapy‐naïve HIV‐infected patients in Cameroon: a case–control study , 2010, HIV medicine.

[17]  O. Kirk,et al.  Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study * , 2011, HIV medicine.

[18]  L. Kuller,et al.  Lipoprotein particle subclasses, cardiovascular disease and HIV infection. , 2009, Atherosclerosis.

[19]  M. Egger,et al.  Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring , 2009, AIDS.

[20]  R. Napoli,et al.  Human immunodeficiency virus per se exerts atherogenic effects. , 2009, Atherosclerosis.

[21]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit , 2007, European heart journal.

[22]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[23]  O. Kirk,et al.  The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D:A:D Study , 2006, HIV medicine.

[24]  D. Arveiler,et al.  Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  E. Stein,et al.  Estimating the long-term effects of storage at -70 degrees C on cholesterol, triglyceride, and HDL-cholesterol measurements in stored sera. , 2000, Clinical chemistry.

[26]  P. Barter.  International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia. , 2014, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[27]  C. Daniyam,et al.  Lipid Profile of Anti-Retroviral Treatment-Naïve HIV-Infected Patients in Jos, Nigeria , 2013, Annals of medical and health sciences research.

[28]  M. Marfell-Jones,et al.  International standards for anthropometric assessment. , 2012 .

[29]  A. Schutte,et al.  Lipid Abnormalities in a Never-Treated HIV-1 Subtype C-Infected African Population , 2009, Lipids.

[30]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[31]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[32]  Peter Piot,et al.  Joint United Nations Program on HIV/AIDS (UNAIDS) , 1997 .